IDO2 and neoplasm: Furthermore, an inhibitor of indoleamine 2,3-dioxygenase was loaded into the PD-1 modified EVs, which inhibited the immunosuppressive pathway, leading to increased tumor infiltration of CD8+ T cells and tumor regression.